Dr RR Baliga's "Got Knowledge Doc" Podkast

💡 Fresh insights from a randomized crossover trial in people with Type 2 Diabetes (T2D)! 🍽️🚶‍♂️ High-fat 🥑 and high-carb 🍞 meals, with or without a light post-meal walk, showed no adverse effects on cardiac autonomic modulation or ECG intervals. ✅ Heart rate variability held steady, and walking even gave a gentle boost without risk. 🫀 Key Takeaway: Flexible dietary choices and safe postprandial walking may support everyday life in T2D without destabilizing the heart. #DiabetesCare #Cardiology #HRV #LifestyleMedicine #ClinicalResearch #ExerciseIsMedicine #NutritionScience #AutonomicFunction #ScientificReports 📊

🚨 New Insights in Dilated Cardiomyopathy (DCM)! 🫀 Fibroblasts aren't just bystanders — they're mechanical rheostats shaping disease severity. 🧬 This groundbreaking study shows that blocking p38 signaling halts fibrosis, boosts contractility, and may redefine how we treat DCM. 💥 🧠 Think beyond myocytes. Think collective cell behavior. 🧪 Read the full paper in Science: "Preventing Hypocontractility-Induced Fibroblast Expansion Alleviates DCM" #Cardiology #HeartFailure #Fibrosis #ECM #PrecisionMedicine #Fibroblasts #DCM #p38MAPK #HeartResearch #TranslationalMedicine 🧵

🚨 New frontier in #NeuroRehab & #BioelectronicMedicine! Just explored two groundbreaking studies on autonomic dysreflexia and implantable neurostimulation in spinal cord injury (SCI) 🧠💥 ⚡ One reveals the neuronal circuitry driving dangerous BP spikes 🔌 The other shows how epidural stimulation at T11–L1 can restore BP within 2 minutes 💡 Together, they mark a paradigm shift—from managing symptoms to rewiring circuits. #SCI #SpinalCordInjury #Neuroscience #CardiovascularHealth #ImplantableDevices #Dysreflexia #LinkedInLearning #PodcastDrop #Innovation #ClinicianScientist

🫀 NEWTON-CABG Trial: Can intensive LDL-C lowering prevent vein graft failure after CABG? 💉 Evolocumab slashed LDL-C by ~50%, but did not improve SVG patency at 2 years. Why? Timing is everything. 🧠 Early SVG failure = thrombosis & hyperplasia—not classic atherosclerosis. LDL-C ≠ magic bullet here. #Cardiology #CABG #LDL #PCSK9 #Evolocumab #CardioTrials #Lipids #HeartHealth #GraftPatency #ClinicalResearch #JACC #TheLancet #SurgeryMeetsPrevention

🧠💤 Why do we sleep? A groundbreaking Neuron article explores this timeless question through a bold new lens: 🛌 The Motor Theory & Catecholamine Hypothesis of Sleep. Instead of a single "sleep center," 🧬 sleep emerges from distributed motor control circuits regulating both somatic & autonomic activity. And the "why"? 😴 Suppressing dopamine, noradrenaline & adrenaline may be key to healing our brain, body, & immune system. 📉 Sleep isn't passive—it's active neural choreography for recovery. 📚 Read if you're into neuroscience, systems biology, or sleep medicine. 🔗 https://www.cell.com/neuron/fulltext/S0896-6273(25)00623-3 #SleepScience #Neuroscience 🧠 #MotorTheory #Catecholamines #Neuron #PrecisionMedicine #BrainHealth #SleepResearch #WhyWeSleep #SystemsBiology

🚨 New insights from the Lancet! 🚑 In the OPTION–STEMI trial, immediate multivessel PCI during the index procedure failed to show non-inferiority compared to staged revascularisation in STEMI patients with multivessel disease. 🧠 Key takeaway? Timing matters. ⚠️ Higher risk in those with heart failure (Killip II/III) 💡 Safer strategy: staged PCI for high-risk patients 📊 Fractional flow reserve, procedural MI, and guideline implications all in focus. A must-read for interventionalists & clinical guideline leaders. 🔗 https://doi.org/10.1016/S0140-6736(25)01529-6 #STEMI #PCI #InterventionalCardiology #Lancet #CardioTwitter #Revascularisation #KillipClass #FFR #ClinicalTrials #Cardiology ❤️🫀

✨ St. Thomas Aquinas (1225–1274) — Dominican friar, philosopher & theologian — is among the most influential thinkers in Western tradition. 📖 His Summa Theologica shaped Catholic theology, blending Aristotle's philosophy with Christian faith. 🕊️ Known as the Doctor Angelicus, he championed faith & reason, natural law ⚖️, and virtue ethics 💡— principles that still guide philosophy, theology, and even modern healthcare ethics 🏥. 🌍 #Philosophy #Theology #Healthcare #Leadership #Wisdom

🚨 New Podcast Drop! 🎙️ "VICTOR, Vericiguat, and Victory?" unpacks the Lancet trilogy — the VICTOR trial, pooled analysis, and expert commentary 🧠📊💊. We explore Vericiguat's evolving role across the heart failure spectrum 💓📉 and what it means for clinical care in HFrEF patients. 📚 Trials discussed: VICTOR, VICTORIA 🎧 Tune in for insights on risk-based treatment effects, NT-proBNP thresholds, and more! #HeartFailure #Vericiguat #HFrEF #Lancet #Cardiology #RCT #NTproBNP #Podcast #MedicalEducation #EvidenceBasedMedicine

🎭 Just explored a landmark Nature Medicine review on how the arts can prevent noncommunicable diseases (NCDs) across 27 countries! 🎨 From dance and drama to gardening and storytelling, arts-based interventions improved physical activity, diet, and mental well-being—especially in underserved communities. 📊 A must-read for anyone interested in health equity, cultural relevance, and community-led innovation in public health. 👇 Dive into the power of creativity for prevention! #NCDs #ArtsInHealth #HealthEquity #PublicHealth #SocialDeterminants #GlobalHealth #PreventionMatters 🎶🌱📚🩺

💊 Orforglipron: A new era in obesity treatment? In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️ 🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies Accessible. Effective. Oral. 👉 A game-changer for global obesity care? #Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy

🚨 New Podcast Drop! 🎙️ "Myosin, Metrics & Momentum 🧬📈🫀" dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy. We decode: 🔹 MAPLE-HCM (obstructive HCM) 🔹 ODYSSEY-HCM (nonobstructive HCM) 🔹 Expert editorial insights on PROs, EF, & trial design 🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the road ahead in precision cardiomyopathy care. 🎧 Tune in and share! #HCM #CardioTwitter #NEJM #HeartFailure #MyosinInhibitors #Podcast

💊 New Hope in a Pill for Obesity? The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss, improved physical function, and reversed prediabetes in 71% of cases—all without injections. 📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered. #ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬 New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉 From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Let's talk melanin, mortality, and medicine! 🌍💡 #Sunlight #CardiovascularHealth #TheEconomist #PublicHealth #MedicalEducation

🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade. 📊 This changes how we think about long-term outcomes in mechanical support. 🔗 Time to revisit your shock protocols? #DanGerShock #Impella #CardiogenicShock #STEMI #LongTermOutcomes #NEJM #MCS #Cardiology #SurvivalBenefit #ImpellaCP

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬 📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare's first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. 💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read. 📉 SCD prevention, 🫀 LVOT obstruction, 🧪 MYBPC3/MYH7 mutations, 🧬 proteomics, and more. 🔗 Essential reading for cardiologists, geneticists, and translational scientists. #HCM #Braunwald #NEJM #Cardiology #PrecisionMedicine #Mavacamten #Aficamten #GeneTherapy #MedicalEducation #SCDprevention

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥 ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions 🔬 APOC3 inhibition emerges as a game-changer in lipidology. 📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI #Atherosclerosis #GenomicTherapy 🧬💊🫀

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—"just sitting" 🧘‍♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics 🧓📉

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care. 🔗 #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA #ALONEAF #Electrophysiology #SharedDecisionMaking #ClinicalTrials

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75) 🧠 Key Takeaway: Routine screening isn't broadly warranted—but targeted testing in high-risk AMI patients may be the smarter path forward. 📊 #Cardiology #Gastroenterology #HPylori #HELPMI #EvidenceBasedMedicine #SWEDEHEART #MI #GIbleeding #RCT #PrecisionMedicine

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let's rethink how we label, risk-stratify, and treat. 📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨ #Leadership #Philosophy #History #Confucianism

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5%. No serious adverse events. And yes — better gait speed, handgrip strength, and quality of life too. This is how we shift from survival ➡️ functional independence in aging populations. 🙌 👇 Would you apply this model to your older patients post-MI? #CardioRehab #AgingWell #NEJM

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)? 📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clinical heart failure. 🌍 Consistent across trials and countries. Most benefit seen in patients 📚 This could shift guidelines for a large overlooked population. 🔗 Read more in The Lancet (Aug 30, 2025) #Cardiology #BetaBlockers #MyocardialInfarction #LVEF #EvidenceBasedMedicine #MetaAnalysis #HeartHealth 💓📉

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%). 💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Signals of potential harm in women and STEMI subgroups raise questions, not answers. 📉 Should guidelines change? Or should practice just evolve? #Cardiology #REBOOTTrial #BetaBlockers #NEJM #PrecisionMedicine #MedicalEducation #HeartAttack #LVEF #Guidelines #ClinicalTrials #InternalMedicine #EvidenceBasedMedicine #Revascularization

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there's no heart failure? 🤔 In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉 📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p=0.03 💡 Especially lowered risk of recurrent MI (HR 0.73) 🧠 Even in the era of PCI, DAPT & statins, beta-blockers may still bring benefit — especially in patients with mildly reduced LVEF (40–49%) 🫀 🔗 [Add your slide link or DOI here] #Cardiology #NEJM #HeartAttack #BetaBlockers #PostMI #EvidenceBasedMedicine #LVEF #PrecisionMedicine #ClinicalTrials

💥 New NEJM Trial Alert! A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀 📉 HR 0.76 for the composite endpoint 🔢 NNT = 12.3 over 3.3 years 🍌 Safe, scalable, and globally relevant 👉 Time to rethink "normal" K⁺ levels in cardiology! #Cardiology #Electrophysiology #NEJM #ICD #Potassium #POTCAST

🚨 New RCT Alert from the NEJM! Can an old 💊 make a comeback in modern 💓 failure care? 📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i. 🩺 HR = 0.82; p = 0.03 📉 👩‍⚕️ Safe in CKD, consistent benefit in women. ⚠️ Serious AEs slightly higher (4.7% vs 2.8%) 📥 NNT = 22. 💡Is it time to reconsider digitoxin in advanced HFrEF? #CardioTwitter #HFrEF #HeartFailure #Digitoxin #NEJM #Cardiology #SGLT2i #GuidelineTherapy

🚨 Calcific Aortic Valve Stenosis (CAVS): Beyond Wear and Tear 🫀🪨 Once thought to be "degenerative," CAVS is now recognized as an active disease driven by oxidative stress ⚡, inflammation 🔥, and lipoprotein(a) 🧬. Despite its growing global burden, no drug therapy slows its progression. 🩺 Current management: Surgical (SAVR) or Transcatheter (TAVR) valve replacement. 💊 Emerging hope: PCSK9 inhibitors, Lp(a) lowering agents, SGLT2 inhibitors, soluble guanylate cyclase activators, and anti-inflammatory strategies. 📊 Modern tools: Aortic valve calcification on CT, PET imaging for microcalcification, and strain imaging for early detection. 🔑 Takeaway: CAVS is preventable in theory, but not yet in practice. Novel therapeutics may finally reshape its natural history. #Cardiology #HeartValve #PrecisionMedicine #AorticStenosis

🚨 New in The Lancet (2025) 🚨 A mega meta-analysis of 484 RCTs (104K+ participants) offers a game-changing approach to hypertension management! 💊📉 Instead of guessing how much BP will drop, now you can predict it—by drug, dose, and combo! 🎯 Like statins for LDL, this study introduces low-, moderate-, and high-intensity BP regimens based on expected mmHg reductions. 💡 Use the free calculator 🔢 at www.bpmodel.org and rethink the "measure-treat-measure" loop. 🩺 Data-driven. Predictable. Efficient. Just what primary care and cardiology need. #Hypertension #BloodPressure #Cardiology #MetaAnalysis #PrecisionMedicine #Lancet2025 #BPcalculator #MedTwitter #InternalMedicine #DigitalHealth 💻📊🧬

🧒❤️ Partial Heart Transplant: A Growing Solution for Growing Hearts! 🌱🔬 🚨 Pediatric patients with congenital heart valve disease often face multiple surgeries due to non-living valve grafts that don't grow. This landmark study from @DukeHealth shows how living valves via partial heart transplant can change the game. 📊 In 19 patients (median age: 97 days), transplanted valves showed true annular and leaflet growth — with low immunosuppression and no valve-related reinterventions. The innovative "Living Ross" approach offers a promising path for long-term durability. 🧬 Organ stewardship, reduced surgeries, and biologic adaptation — the future is here. 🔗 Read the full JAMA study #PediatricCardiology #HeartTransplant #InnovationInSurgery #LivingRoss #JAMA #CardiacSurgery #ValveReplacement #CongenitalHeartDisease #PartialHeartTransplant #PrecisionMedicine 🫀📈

🐖🫁 World First: Pig Lung Transplanted into Human 🧬🌍 In a groundbreaking step for xenotransplantation, a team in China successfully transplanted a genetically modified pig lung into a brain-dead human recipient. The lung functioned for 216 hours without hyperacute rejection, offering hope to thousands on organ waitlists. 🔬 Key breakthroughs: • 6-gene-edited donor pig • No Porcine Endogenous Retrovirus (PERV-C) detected 🦠 • Controlled immune response 🛡️ • PGD observed but stabilized 💉 📖 Published in Nature Medicine: https://doi.org/10.1038/s41591-025-03861-x 👏 A monumental leap toward clinical trials and saving lives. #Xenotransplantation #LungTransplant #OrganDonation #Immunology #PrecisionMedicine #NatureMedicine #TranslationalScience 🚀

🧬 Pre-Heart Failure? Let Age Speak! 👵👴 New study in JACC compares fixed vs age-adjusted NT-proBNP cutoffs for defining pre–heart failure (Pre-HF) in over 22,000 adults across ARIC, MESA, and CHS cohorts. 📉 Key Insight: Age-adjusted cutoffs reduce overdiagnosis in older adults 🧓 and improve risk prediction for heart failure hospitalization 🏥. 📊 With better C-statistics, NRI, IDI, and a lower number needed to screen, the age-specific approach proves more precise—especially in those ≥75 years. ⚖️ One-size-fits-all doesn't fit the aging heart. Time to tailor biomarkers by age! ⏳❤️ #HeartFailure #NTproBNP #Cardiology #PrecisionMedicine #Biomarkers #PreventiveCardiology #JACC #PreHF #RiskStratification #PopulationHealth

🚨 Game-Changer in Lung Cancer! 🫁💉 The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯 ✅ 65.4% 5-year OS vs. 55.0% with chemo alone 🧬 pCR = 95.3% survival 📉 ctDNA clearance = better outcomes ⚖️ Time to rethink neoadjuvant strategies 📚 Read in NEJM: A landmark in thoracic oncology! #LungCancer #Immunotherapy #NSCLC #Nivolumab #Oncology #CancerResearch #PrecisionMedicine

🚨 New insights from EHJ 2025! 🚨 In statin-treated patients undergoing PCI, inflammation (hsCRP ≥2 mg/L)—not elevated LDL-C—was the strongest predictor of MACE at 1 year 🔥🧪 📊 Bay et al. show that residual inflammatory risk carries a 1.8x higher hazard for adverse events, while LDL-C alone showed no independent risk 💥 🧠 Time to shift focus beyond lipids: consider anti-inflammatory therapies, remnant cholesterol, and Lp(a) in risk stratification 🩺🎯 📖 Read the study ➡️ https://doi.org/10.1093/eurheartj/ehaf196 #Cardiology #Inflammation #ResidualRisk #PCI #Statins #PrecisionMedicine

🔎 Averroes (Ibn Rushd, 1126–1198), the "Father of Rationalism," bridged Islam & the West through philosophy, medicine & law. 🌍 His commentaries on Aristotle, theory of the intellect, and medical insights (stroke, Parkinson's, retina) shaped centuries of thought. 📚 His legacy reminds us that reason, faith & science can coexist in pursuit of truth. 💡 #Philosophy #Medicine #History

🚨 New Study Alert 🧬🫀 Think a CAC score of zero means you're in the clear? Think again. A massive cohort from the Western Denmark Heart Registry (n = 23,777) shows that elevated LDL-C is strongly associated with non-calcified plaque 🧱 and future coronary events 💥—even in those with CAC = 0. 📈 Each 1 mmol/L (~39 mg/dL) rise in LDL-C increases the odds of plaque (aOR 1.21) and risk of CHD (aHR 1.28). 🔥 Risks were highest in individuals ≤45 years—a silent threat during prime decades of life. 💡 Takeaway: No calcium ≠ No risk. LDL-C still drives subclinical disease. 👩‍⚕️👨‍⚕️ Time to rethink statin strategy in younger adults with "reassuring" scans. 📚 Read more in European Heart Journal (2025): 👉 https://doi.org/10.1093/eurheartj/ehaf497 #LDL #CAC #Cardiology #Atherosclerosis #CHD #Prevention #Lipidology #CCTA #PrecisionMedicine #Statins #EHJ #SubclinicalDisease #CardioLinked

🚨 New in NEJM 🫁: The IMPALA-2 trial shows that inhaled molgramostim significantly improves gas exchange, quality of life, and exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP)—a rare disease driven by GM-CSF autoantibodies. 💨 Say goodbye to whole-lung lavage—this is a bench-to-bedside success story 30 years in the making. 🔬 From GM-CSF knockout mice ➡️ inhaled cytokine therapy ➡️ regulatory-grade RCT. 🏆 A major win for translational respiratory medicine. #Pulmonology #RareDiseases #GMCSF #AutoimmuneDisease #Molgramostim #PrecisionMedicine #TranslationalResearch #NEJM #aPAP #LungHealth #RCT #CytokineTherapy #BenchToBedside #InhaledTherapy 🧬🫁💊

🚨 New Stroke Trial Alert! 🧠💉 Can IV alteplase help beyond the 4.5-hour mark? The HOPE trial (JAMA 2025) says YES—if perfusion imaging shows salvageable brain tissue 🧬🕑. 📊 Functional independence at 90 days improved from 26% ➡️ 40%, despite a small uptick in symptomatic ICH (3.8%). 🌍 Game-changer for patients in low-resource settings where thrombectomy isn't an option. 📖 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.12063 #StrokeCare #Thrombolysis #Alteplase #Neuroimaging #HOPEtrial #JAMA #StrokeResearch #GlobalHealth #BrainRescue #MedicalInnovation

🚀 Exciting breakthroughs in metabolic medicine! 💊 This August 2025 Nature Reviews Drug Discovery review by Dr. Daniel Drucker dives deep into the evolution of GLP-1-based therapies—covering semaglutide, tirzepatide, multi-agonists, oral small molecules, and their growing impact beyond diabetes into obesity, liver disease, and neurodegeneration. 🧠⚖️💥 📉 From gut hormones to global health, GLP-1 therapies are redefining chronic disease care. 🔗 Read, reflect, and get ready for what's next: #GLP1 #ObesityMedicine #IncretinTherapies #PharmaInnovation #MetabolicHealth #Tirzepatide #Semaglutide #DrugDiscovery #PrecisionMedicine #Endocrinology 💥

🚨 New insights from the European Heart Journal! 🫀✨ This study shows that where you store fat — not just how much — matters for how your heart and arteries age. 📌 Android fat (belly) = faster cardiovascular aging 📌 Gynoid fat (hips/thighs) = protective, especially in women 🧬 Using MRI (ShMOLLI), metabolomics & AI (CatBoost), researchers predicted cardiovascular age from fat patterns. 💡 A wake-up call for personalized risk, not just BMI! #CardioMetabolic #PrecisionMedicine #VascularAging #SexDifferences #BodyFat #EuropeanHeartJournal #Cardiology 🧠📊🧘‍♀️

👨‍⚕️🔬 Just explored the latest JAMA review on Prostatitis—a masterclass in clarity and clinical relevance! From LUTS to CP/CPPS, it unpacks the full spectrum: 🧪 Meares-Stamey testing, 📊 NIH-CPSI scoring, and 🚀 modern management strategies. A must-read for anyone navigating the nuanced world of male pelvic health. #Urology #MensHealth #Prostatitis #PrecisionMedicine 🧠📘

🚨 New in JACC (Aug 2025): Evidentiary Landscape of HF Therapies 🫀 Over the last decade, the heart failure field has shifted from the "mortality reduction era" (ACEIs, β-blockers, MRAs) ➡️ to the "hospitalization reduction era" (SGLT2i, ARNI in HFpEF, iron therapy). 🔑 Key Insights: ⚖️ FDA decisions reflect both rigor and flexibility — approving sacubitril/valsartan in HFpEF despite a missed primary endpoint, while rejecting omecamtiv mecarbil despite statistical significance. 🧬 Enrichment strategies (NT-proBNP, iron indices, recent WHF) drive modern trial design, boosting efficiency but limiting mortality signals. 📊 Composite endpoints (CV death + HHF) dominate, making hospitalization reduction the most reproducible outcome. 📖 Guidelines now anchor on ARNI + SGLT2i in HFrEF and SGLT2i in HFpEF, with emerging roles for finerenone and incretin-based therapies. 👉 Big picture: Clinical practice is evolving, but the "holy grail" of new mortality-reducing therapies remains elusive. #HeartFailure #Cardiology #ClinicalTrials #FDA #JACC

🧬 Mesenchymal Drift: A New Hallmark of Aging & Disease 🧬 Researchers uncover that Mesenchymal Drift (MD)—the widespread activation of mesenchymal genes across tissues—is a conserved feature of aging and multiple diseases. 📉 High MD = worse outcomes (e.g., in Idiopathic Pulmonary Fibrosis, survival dropped from 1,027 to 294 days). 🔄 Excitingly, partial reprogramming with Yamanaka factors (OSKM) reverses MD before cells lose their identity, restoring youthful transcriptional programs. ✨ This opens the door to new therapeutic strategies for rejuvenation and age-related diseases. #Aging #Longevity #Epigenetics #RegenerativeMedicine #CellBiology

🚨 New insights on atrial fibrillation (AF) treatment! A major meta-analysis in Annals of Internal Medicine 🧠📊 confirms that catheter ablation reduces stroke 🧨, heart failure hospitalizations 🏥, and mortality ⚰️—especially in patients with HF. While surgical ablation with LAA occlusion shows benefit in stroke prevention, catheter-based strategies 💉🔥 continue to lead in outcomes and safety. 💡 Time to rewire rhythm control strategies. #AtrialFibrillation #Cardiology #StrokePrevention #CatheterAblation #HeartFailure #EP #Guidelines #AFib #PrecisionMedicine 🫀💡📈

🚨 New insights from Annals of Internal Medicine challenge long-held beliefs about alcohol 🍷 and health 🧬. A 2025 U.S. Surgeon General advisory links even modest drinking to increased cancer risk 🎗️—especially breast and oral cancers. Experts now urge clearer labeling, better patient counseling 🩺, and culturally normalizing abstinence 🌱. Is it time to rethink the "glass of red wine" advice? 🧐 #PublicHealth #AlcoholAwareness #PreventiveMedicine #AnnalsOfIM

💡 Renal Denervation: A New Era in Hypertension Care 🩺 Despite decades of effective medications, only ~25% of patients worldwide achieve blood pressure control. Non-adherence remains a huge barrier. 📉 This Nature Reviews Cardiology article (Fisher & Kirtane, Sept 2025) explores the journey of renal denervation (RDN) — from Smithwick's sympathectomy in the 1950s to today's FDA-approved radiofrequency 🔥 and ultrasound 🔊 catheter systems. ✅ Sham-controlled trials show RDN lowers BP by 5–10 mmHg, similar to one effective antihypertensive drug. ✅ Durable safety profile, up to 10 years in registries. ✅ Best suited for resistant hypertension, drug intolerance, or pill fatigue. ✅ Implementation requires multidisciplinary teams and shared decision-making. 🤝 🚀 Future: Expanding to underrepresented populations, CKD, elderly, and even beyond hypertension (AFib, sleep apnea, metabolic syndrome). 👉 A fascinating example of how history, technology, and evidence converge to reshape cardiovascular medicine.

📘 New Insights on Diverticulitis 📊🔬💊 Did you know that while 1–4% of people with diverticulosis develop diverticulitis, it still accounts for ~200,000 hospitalizations annually in the US and >$6.3B in healthcare costs? 🚑💰 ✅ CT scan remains the gold standard for diagnosis 🖼️ ✅ Observation & pain control are first-line for uncomplicated cases 💊 ✅ Antibiotics reserved for high-risk groups (elderly, immunocompromised, pregnant, systemic illness) ⚠️ ✅ Surgery indicated for recurrent or complicated cases (fistula, stricture, perforation) ✂️ This JAMA 2025 review emphasizes precision in management—avoiding overtreatment while protecting vulnerable patients 👥. 👉 How do you approach antibiotic stewardship in diverticulitis care?